Mark Delaney: Michael, I uh — I genuinely could not sleep after reading this one, which is funny given what the guy's whole thing is about.
Michael C. Vincent: The irony writes itself, doesn't it.
Mark Delaney: Bryan Johnson — Blueprint, the whole operation, eight-thirty bedtime, hundred-plus supplements, two million dollars a year — goes on X and tells the world his stomach is eating itself. That's the actual quote. Autoimmune gastritis. His immune system is attacking his own stomach lining. And there's no cure. That's what we're figuring out today, like, what do we do with that?
Michael C. Vincent: What we do with it starts with the ferritin. Before the endoscopy confirmed this in 2026 — the biopsies, the elevated autoimmune markers — there were already over ten years of persistently low ferritin sitting in his biomarker data.
Mark Delaney: Ferritin. That's — wait, that's not some exotic marker, that's basic bloodwork stuff.
Michael C. Vincent: It is not exotic. It is foundational. And it was there, waving, in the dataset of a man tracking over a hundred biomarkers. Flagged. Dismissed by physicians. Retroactively: the earliest sign.
Mark Delaney: Man. That's the story, right there — that's the whole thing before we even get going.
Michael C. Vincent: That is precisely where the story begins.
Mark Delaney: But I can't get past this — he wasn't ignoring his ferritin, right? Like, he was tracking it. It was in the system. So what actually went wrong?
Michael C. Vincent: That is the clarifying point. The headline says Blueprint failed him. The real story is stranger and more specific. Imagine a smoke detector in every room of your house — and it beeps, faintly, for ten years. You note it, swap the battery, move on. That's ferritin. One number, chronically low, sitting alongside a hundred other numbers that all looked fine.
Mark Delaney: And because the other stuff looked fine — hemoglobin, hematocrit, all that — nobody chased the one thing that didn't.
Michael C. Vincent: Exactly that. Ferritin is how your body stores iron. When it runs persistently low, something is consuming it upstream. Autoimmune Gastritis was destroying his parietal cells — those are the cells that allow iron to be absorbed in the first place. But catching that required a camera inside him. A bi-directional endoscopy, biopsies, elevated autoimmune markers on bloodwork that wearables simply do not generate.
Mark Delaney: Wait — so the DunedinPACE clock, the heart-of-a-37-year-old readings, skin of a 28-year-old, lungs performing like an 18-year-old athlete — those numbers were real, but coming from a body that was already under attack?
Michael C. Vincent: Yes. And that's not a contradiction — that's the mechanism. The biomarker monitoring wasn't wrong. His epigenetic aging rate really does clock at 0.64 years per chronological year on the DunedinPACE. But those metrics measure what they measure. None of them were designed to catch a slow autoimmune assault on the stomach lining. The system read selectively because it was built selectively.
Mark Delaney: So it's not — uh, it's not that he was drowning in noise and missed it. It's that the signal existed in a format his whole apparatus couldn't translate.
Michael C. Vincent: That's the heart of it. One clean sentence: the measurement wasn't wrong, but it was being read by a system with no vocabulary for what was actually happening.
Mark Delaney: And the thing that finally named it was the most low-tech move imaginable — a doctor with a camera and a biopsy needle.
Michael C. Vincent: Which is the thing that should unsettle the 'price of arrogance' framing the NY Post ran with — and half the internet echoed. That framing is satisfying. It is also slightly wrong. Autoimmune Gastritis is a genetic-autoimmune event. You cannot optimize your way out of your own genome.
Mark Delaney: Wait — so the diagnosis isn't, like, what happened when he pushed too hard?
Michael C. Vincent: His arrogance didn't cause AIG. But it may have done something almost worse — it gave him a framework for explaining the signal away. A decade of low ferritin, and the system kept saying: everything else checks out.
Mark Delaney: Okay but — uh, I mean, that's a real distinction. Those are two different charges. Caused it versus missed it. One's on Blueprint, one's on how Blueprint gets used.
Michael C. Vincent: And the 'arrogance' framing collapses them into one, which lets him off the hook in a peculiar way. If the disease is his fault, it's personal. If the disease just happened — well, then we have to look at what the response reveals.
Mark Delaney: Right — and the response is wild. He doesn't accept it, he announces immune system mapping, launches 'Bryan in a dish,' a whole personalized precision-medicine platform aimed at finding the exact cells attacking his stomach. That's not grief. That's... I don't even know what that is.
Michael C. Vincent: It's transhumanism made literal. Blueprint was always built on the premise that technology can transcend biological limits — aging, disease, the body's own entropy. Now he's facing something genuinely incurable and the framework simply cannot generate a different answer. More precision medicine. More data. The mindset isn't courageous or deluded — it's structurally incapable of saying 'this is the wall.'
Mark Delaney: So the diagnosis doesn't challenge Blueprint. It just becomes Blueprint's next problem to solve.
Michael C. Vincent: Exactly. And that might be its own kind of blindness — the same one that held the ferritin story for eleven years. What that means for 'Bryan in a dish' specifically, and whether the democratization promise behind Blueprint survives scrutiny at all — that's the part we haven't gotten to yet.
Mark Delaney: And that gap — between what he can do and what anyone else can do — that's where the democratization story falls apart for me. Like, he launches Immortals, right? A million dollars a year. That's the exact protocol he's followed for five years, now with a price tag on it.
Michael C. Vincent: A million dollars a year.
Mark Delaney: But Empirical Health looked at that protocol and found — uh, this is the number that kinda stopped me — ninety percent of the value can be replicated for under two thousand dollars a year. Blood work, diet, exercise, sleep. That's it. That's the part that actually has evidence behind it.
Michael C. Vincent: And what sits in the remaining ten percent — the price premium — is the thirty-person medical team, the immune mapping, 'Bryan in a dish.' The experimental architecture. Which no one else can access.
Mark Delaney: Which is also, by the way, the part that just — I mean, it's the part that didn't catch AIG for eleven years. The two-million-dollar apparatus with all the biomarker monitoring. So the stuff regular people actually can access is the proven stuff. And the stuff they can't is the experimental stuff. And the experimental stuff just failed its most public test.
Michael C. Vincent: I'd be careful calling it a failure — 'Bryan in a dish' hasn't run yet. But picture it: someone gets a continuous glucose monitor after hearing Casey Means on a podcast, starts tracking HRV because Robert F. Kennedy Jr. mentioned wearables, sees this story — and thinks, if two million dollars and thirty doctors missed this for a decade, what am I even doing?
Mark Delaney: That's — yeah, that's the person I keep thinking about.
Michael C. Vincent: And the honest answer for that person is: the Blueprint evidence base is not uniform. Sleep science — solid. Exercise — solid. Many of the hundred-plus supplements are running on animal studies or theoretical data. And when you adjust dozens of interventions simultaneously in an n-of-one experiment, you cannot isolate what helped, what did nothing, and what was noise. That's not cynicism — that's just what the science allows.
Mark Delaney: So the part that's accessible — blood work, diet, sleep, movement — that's the part with actual backing. And the part that costs a million dollars a year is purely experimental. And right now, the person running that experiment has an incurable autoimmune condition it didn't prevent. That's what to watch.
Michael C. Vincent: And if the answer to every diagnosis is another experiment — at what point does measurement stop being science and start being something else entirely.
Mark Delaney: Yeah. I mean — I don't know. I genuinely don't. A 48-year-old with a 30-person medical team, over a hundred biomarkers running continuously, two million dollars a year — and the thing that finally named it was a biopsy. So what does it cost, you know, not financially, but like... what does it actually cost a person to build their whole identity around the idea that limits are just problems nobody's solved yet? When the limit shows up anyway.
Michael C. Vincent: That's the one I don't have an answer to.
Mark Delaney: No. Me neither. Thanks for thinking through it with me, man. This one sat differently.
Michael C. Vincent: It should sit differently. That's probably the point.
